BDSX customer map: concentrated payers, short contracts, and a critical Medicare dependency

Biodesix (ticker BDSX) operates as a two-pronged diagnostic services business: clinical lung diagnostic testing sold to healthcare providers and reimbursement payers, and development services sold to biopharmaceutical and life‑science customers. The company monetizes through fee-for-service reimbursements from payers (government and commercial) and contracted development work for large pharma customers, with revenue recognized on completion of testing or milestones. For investors, the central investment thesis is straightforward: top-line growth scales with payer reimbursement and biopharma contract wins, while downside is driven by payer concentration and short-term commercial contracts.
Learn more about exposure mapping and customer-level signals at https://nullexposure.com/.

How revenue is split and what that implies for operating risk

Biodesix discloses two revenue streams—Lung Diagnostic Testing and Development Services—and recognizes revenue when performance obligations are satisfied, reflecting a services-oriented business model with discrete deliverables. The company’s receipts come primarily through third‑party payers and direct contract work for large pharmaceutical customers. This structure produces predictable per‑engagement economics but exposes the firm to payer reimbursement dynamics and concentrated counterparty balances.

Revenue concentration is material and asymmetric. Medicare accounted for 39% of total revenue in FY2024 (43% in FY2023), establishing Medicare as a central cash flow driver and a single-point concentration risk. According to Biodesix’s FY2024 Form 10‑K, Medicare reimbursed 39% of total revenue in 2024 and 43% in 2023.
Contracting posture is short-term and terminable. The company states that testing services are generally completed within a year and that certain group purchasing organization (GPO) and integrated delivery network (IDN) contracts are terminable on 60–90 days’ notice, signaling limited long‑dated revenue lock‑in.

These characteristics create a dual profile: stable per-test economics with volatile topline exposure to payer policy and client retention. If reimbursement levels or Medicare policy shift, revenue swings will be immediate given short contract horizons.

Contracting, collectability and counterparty mix — the operating constraints

Biodesix’s disclosures produce a consistent set of operating signals:

Short-term, milestone- or delivery-driven contracts. Services are generally completed within one year and revenue is recognized on completion or at contractual milestones, which makes revenue timing tightly linked to workload and payment cycles.
Counterparty mix includes government payers and large enterprise biopharma customers. The company identifies government payers (explicitly Medicare) and commercial payers, and separately notes that development services customers are typically large biopharmaceutical companies where collectability is reasonably assured.
Geographic concentration in North America. Substantially all revenue and long‑lived assets are U.S.-based, concentrating regulatory and reimbursement risk in the U.S. healthcare system.
Services segment dominant. Both Lung Diagnostic Testing and Development Services are service lines, reinforcing the company’s dependence on recurring test volumes and contracted projects rather than product royalties or annuities.

These constraints shape capital allocation choices: working capital management, collections discipline, and payer contracting strategy are primary levers for near-term performance. For enterprise customers, pricing and milestone structure limit receivable duration, but the Medicare share makes reimbursement policy the main systemic risk.

Learn more about customer exposures and how they affect valuation at https://nullexposure.com/.

Relationship-by-relationship read (from the FY2024 10‑K)

Below are the customer relationships disclosed in the company’s FY2024 filing. Each entry is summarized in plain English with its public source.

Medicare — Medicare reimbursed 39% of Biodesix’s total revenue in FY2024 and 43% in FY2023, establishing it as the company’s largest single payer and a critical revenue dependency. According to the company’s FY2024 Form 10‑K, Medicare accounted for 39% of total revenue in 2024 and 43% in 2023.
United Healthcare — United Healthcare represented 7% of total revenue in FY2024 and 10% in FY2023, indicating meaningful commercial-payer exposure that declined year-over-year. The FY2024 10‑K lists United Healthcare as 7% of revenue in 2024 and 10% in 2023.
UnitedHealthcare (tagged entry) — The filing also records UnitedHealthcare specifically in revenue disclosure members for 2023, corroborating the company’s reporting of a commercial-payor relationship in prior periods. The FY2024 10‑K includes UnitedHealthcare as a named customer in its customer-concentration disclosures for 2023.
Daiichi Sankyo (DSKYF) — Daiichi Sankyo accounted for 14% of accounts receivable as of December 31, 2024 (up from 8% in 2023), making it a significant enterprise customer on the balance sheet side even if not listed as a top revenue contributor. The FY2024 10‑K reports Daiichi Sankyo at 14% of accounts receivable at year-end 2024 and 8% at year-end 2023.

Each relationship carries different risk vectors: Medicare drives reimbursement policy risk and revenue concentration; United Healthcare represents commercial payer leverage and pricing negotiation risk; Daiichi Sankyo reflects development-services receivable concentration tied to project timing and milestone billing.

Investment implications: concentration, collections, and optionality

Concentration risk is the dominant short-term valuation lever. With Medicare supplying nearly two‑fifths of revenues in FY2024, reimbursement policy changes or enrollment shifts would have an immediate top-line impact.
Collections and cash conversion come into focus because of AR concentration. Medicare and Daiichi Sankyo represent large portions of accounts receivable (Medicare 21% of AR in 2024; Daiichi Sankyo 14% in 2024), meaning working capital swings are linked to these counterparties’ payment timing. The FY2024 10‑K records Medicare at 21% of accounts receivable and Daiichi Sankyo at 14% as of Dec 31, 2024.
Commercial and pharma contracts provide diversification but are short-term. Development Services customers tend to be large biopharma companies with assured collectability, but contracts are structured around deliverables and milestones that complete within a year, limiting durable revenue visibility.

For investors, the valuation case rests on two paths: either reimbursement stability and expanding commercial payer adoption reduce concentration risk, or Biodesix grows its development services pipeline with multi-phase engagements that increase revenue visibility and lower payer dependence.

If you want a deeper breakdown of customer exposures and the implications for credit and valuation, explore our exposure tools at https://nullexposure.com/.

Bottom line and actions for investors

Biodesix is a services-first diagnostics company whose cash flows are highly sensitive to payer reimbursement and receivable concentration. Medicare is the single largest revenue lever; commercial payers and large pharma customers provide diversification but under short-term contractual terms. Investors should focus on reimbursement trends, receivable aging for major counterparties, and the company’s ability to convert development wins into repeatable revenue.

To evaluate these exposure dynamics in more detail and monitor updates to customer disclosures, visit https://nullexposure.com/ for ongoing coverage and tools that map counterparty risk to valuation.